/BCT.TO

BCT.TO Stock - BriaCell Therapeutics Corp.

Q: What is the analyst price target for BCT.TO?

Analyst price target information is not currently available for BCT.TO.

Q: What is BCT.TO's market cap?

Market capitalization information is not currently available for BCT.TO.

Healthcare|Biotechnology|TSX

$12.99+3.84%

+$0.48 (+3.84%) • Dec 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $14.29

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BCT.TO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.92

52W High$139.50

52W Low$8.40

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-147,893	$-114,036	$-20,490	$-19,385	$-19,441
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-37,733,686	$-46,021	$-23,272,000	$-15,289,000	$-6,973,000
Net Income	$-36,495,163	$-6,615	$-20,302,000	$-11,581,000	$-2,895,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-86.25	$-4.28	$-19.79	$-25.70	$-46.73

Company Overview

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Visit Website

Earnings History & Surprises

BCT.TO

Beat Rate

50%

Last 14 quarters

Avg Surprise

-37.0%

EPS vs Estimate

Beats / Misses

7/7

Last 12 quarters

Latest EPS

$-6.10

Q4 2025

EPS Surprise History

Q1 24

-255.0%

$-0.71vs$-0.20

Q2 24

+120.0%

$0.11vs$-0.55

Q4 24

+86.5%

$-0.07vs$-0.52

Q4 24

+47.6%

$-0.22vs$-0.42

Q1 25

-20.1%

$-2.33vs$-1.94

Q2 25

+6.8%

$-1.64vs$-1.76

Q4 25

No data

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 10, 2026	—	—	—	—
Q4 2025	Dec 15, 2025	—	$-6.10	—	—
Q4 2025	Oct 16, 2025	—	$-13.37	—	—
Q2 2025	Jun 16, 2025	$-1.76	$-1.64	+6.8%	✓ BEAT
Q1 2025	Mar 12, 2025	$-1.94	$-2.33	-20.1%	✗ MISS
Q4 2024	Dec 12, 2024	$-0.42	$-0.22	+47.6%	✓ BEAT
Q4 2024	Oct 28, 2024	$-0.52	$-0.07	+86.5%	✓ BEAT
Q2 2024	Jun 14, 2024	$-0.55	$0.11	+120.0%	✓ BEAT
Q1 2024	Mar 18, 2024	$-0.20	$-0.71	-255.0%	✗ MISS
Q4 2023	Dec 14, 2023	$-0.18	$-0.50	-177.8%	✗ MISS
Q4 2023	Oct 25, 2023	$-0.40	$-0.14	+65.0%	✓ BEAT
Q2 2023	Jun 14, 2023	$-0.35	$-0.32	+8.6%	✓ BEAT
Q1 2023	Mar 15, 2023	$-0.35	$-0.77	-120.0%	✗ MISS
Q4 2022	Dec 14, 2022	$-0.33	$-0.07	+78.8%	✓ BEAT
Q4 2022	Oct 27, 2022	$-0.30	$-1.02	-240.0%	✗ MISS
Q2 2022	Jun 13, 2022	$-0.19	$-0.32	-68.4%	✗ MISS
Q1 2022	Mar 14, 2022	$-0.16	$-0.24	-50.0%	✗ MISS
Q4 2021	Dec 15, 2021	—	$-1.79	—	—
Q4 2021	Nov 26, 2021	—	$-0.18	—	—
Q2 2021	Apr 30, 2021	—	$0.62	—	—

Frequently Asked Questions about BCT.TO

What is BCT.TO's current stock price?

BriaCell Therapeutics Corp. (BCT.TO) is currently trading at $12.99 per share. The stock has moved +3.84% today.

What is the analyst price target for BCT.TO?

No analyst price targets are currently available for this stock.

What sector is BriaCell Therapeutics Corp. in?

BriaCell Therapeutics Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSX exchange.

What is BCT.TO's market cap?

BriaCell Therapeutics Corp. has a market capitalization of $0.02 billion, making it a small-cap company.

Does BCT.TO pay dividends?

No, BriaCell Therapeutics Corp. does not currently pay a dividend to shareholders.